Bernard A. look Pharm.D.;([unkeyab...

Bernard A. look Pharm.D.;([unkeyable]) Timothy H. Self, Pharm.D.;([unkeyable]) Richard L Lalonde, Pharm.D.;(Section) and Michael B Bottorff, Pharm.D.(Section)

Calcium channel blocker have risen to a position of prominence in clinical medicine. now passing applications include treatment of hypertension, supraventricular arrhythmias, angina pectoris, and peripheral vasospastic disease. In addition, the calcium channel blocker exhibit to promise for use in certain pulmonary diseases, GI disorders, seizure disorders, and migraine headache. With this broad range of clinical applications and widespread use results the potential risk for adverse remedy interactions between the calcium channel blocker and concomitant physic therapies employed in the treatment of these or other disease states.

Many case reports have surfaced lately regarding interactions between the calcium channel blocker and medicines which undergo hepatic metabolism. Although a certain of these reports have been well documented, others have not. Controll studies have been guidanceed to determine the nature, magnitude and clinical significance of the observ interactions, repeatedly with conflicting results. Our project is to critically review the reports and studies concerning the imports of calcium channel blockers forward hepatic drug metabolism. An additional goal is to provide guidance for the clinician faced with the ne for concomitant physic therapy with the calcium channel blockers

The heterogeneous adjusts classified as calcium channel blocker are chemically dissimilar nevertheless share the property of inhibiting calcium ion lax state through slow-channels in myocardial, flat muscle, and specialized conductive tissues. commonly only diltiazem, nifedipine, verapamil, and nitrendipine are approved for use in the United States, and the majority of reports matter these agents.

MARKER COMPOUNDS

Several studies have been waysed to characterize the effects of the calcium channel blocker onward liver blood flow and hepatic enzyme activity, the brace main determinants of hepatic mix with drugs metabolism.[1] These studies have involved the coadministration of the various calcium channel blocker and indocyanine blooming (ICG) or antipyrine, marker unites for liver blood flow and hepatic oxidative enzyme activity, respectively.

The disposition of remedys with large hepatic extraction ratios may be significantly altered according to increases in liver blood follow during the absorption phase, resulting in increased bioavailability between the sides of reduction of the first-pass general intent Increased blood flow will also increase the systemic clearance of these physics Studies indicate that nifedipine, nisoldipine, and verapamil give rise to increases in liver blood deliquesce of approximately 30 percent and consequently might alter the disposition of highly extracted unsalable articles while diltiazem has no significant general intent on liver blood flow.[2-4] The clinical importance of these changes in liver offspring flow has not been clearly established.

Antipyrine studies with calcium channel blocker have shown no change in antipyrine oxidation as a arise of nifedipine coadministration.[2] Diltiazem[2,5-7] and verapamil[2,6,8,9] were the two shown to decrease total clearance of antipyrine (diltiazem 13 to 28 percent; verapamil 12 to 33 percent) and to increase its elimination half-life (diltiazem 12 to 44 percent; verapamil 15 to 50 percent) Diltiazem and verapamil have been further studied[5,6,9] and shown to decrease the formation of the three major antipyrine metabolites. Data from studies according to Bauer et al,[2] Abernethy et al,[6] and Bottorff et al[7] refer to that diltiazem and verapamil exhibit dose-dependent inhibition of antipyrine elimination. Diltiazem doses of 120 mg/day,[2] 270 mg/day,[7] and 360 mg/day[6] produc antipyrine clearance decreases of 13 percent 18 percent and 28 percent respectively. Likewise, verapamil doses of 240 mg/day[2] and 480 mg/day[6] were associated with decreases in antipyrine clearance of 13 percent and 30 percent respectively.

These studies indicate that nifedipine has little or no measurable drift on hepatic oxidative enzyme activity (as assessed on antipyrine disposition). Diltiazem and verapamil, in succession the other hand, produce significant inhibition of these enzyme particularly at higher horizontals of dosing, which may provide a basis for clinically significant interactions with remedys eliminated by oxidative metabolism.

THEOPHYLLINE

Theophylline metabolism is known to be pendent on hepatic oxidative enzyme activity, which may be altered according to calcium channel blockers. Early case reports[10-12] implicating verapamil and nifedipine as agents interacting with theophylline elimination were inadequately documented. later controlled studies involved single-dose[13,14] and multidose[15,16] therapy with theophylline in combination with nifedipine, verapamil, and diltiazem.

Nifedipine has been shown to change theophylline clearance in a range from -9 to +10 percent in three controll trials.[13,15,16] These equivocal findings glance at no clinically significant interaction.